The problem of motor side effects associated with antidepressants is relevant in the elderly. Elderly people are physically more frail and more likely to be suffering from physical illness and any drug may exacerbate preexisting disease or interact with other treatments. Several drugs used for psychiatric diseases may induce motor side effects, which are particularly prominent in the elderly. A well known example is supplied by the Parkinson-like motor side effects caused by classical antipsychotics such as haloperidol to which the elderly are particularly sensitive. Less known is that antidepressants may also induce motor side effects. This paper reviews the biological bases of this phenomenon examining the interplay between neuronal circuits involved in motor and emotional control, aging, disease and the effect of antidepressants on these systems. This knowledge may provide a rationale to understand or foresee motor side effects of antidepressants, helping to avoid or at least to prevent their consequences.
MILLENNIUM ARTICLE
The search for complex disease genes: fault by linkage or fault by association?
M Baron
This overview contrasts two pivotal methods for genefinding strategies: linkage analysis and association mapping. Linkage analysis has been used successfully to identify the genes underlying rare mendelian disorders. It has also played a role in attempts to map genes for common non-mendelian (also known as 'complex' or 'multifactorial') diseases such as psychiatric disorders. Uncertainties about the utility of the linkage approach for complex genetic traits has spurred interest in association studies with candidate genes, as an alternate strategy. Recently, with the advent of new molecular tools, in particular high-density, singlenucleotide polymorphisms (SNPs) maps, it has been argued that, while linkage analysis may retain some role, genome-wide association studies with SNPs offer a superior strategy for unraveling genetic complexity. This paper reviews these issues, stressing the pros and cons of the various strategies. The author proposes that: (1) the uncertainties in association studies may have been underestimated; (2) neither method is sufficient or optimal; and (3) a joint linkage and association approach, together with genomic, statistical and computational advances, may have greater promise for understanding the genetic underpinnings of complex disorders in the new millennium.
ORIGINAL RESEARCH ARTICLES
Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder AM Persico, L D'Agruma, N Maiorano, A Totaro, R Militerni, C Bravaccio, TH Wassink for the CLSA, C Schneider, R Melmed, S Trillo, F Montecchi, M Palermo, T Pascucci, S Puglisi-Allegra, K-L Reichelt, M Conciatori, R Marino, A Baldi, L Zelante, P Gasparini, F Keller Autism is viewed as a complex neurodevelopmental disorder. Reelin is critically involved in the development of many brain regions displaying alterations in autistic patients. The authors have identified a repeated GGC sequence in the gene encoding Reelin that might affect gene expression. This GGC stretch is 'polymorphic', meaning it differs in length among different individuals. Approximately 90% of the general population carries either eight or 10 GGC repeats. Interestingly, longer variants encompassing 11-23 GGC Molecular Psychiatry repeats are found in as many as 20% of autistic patients, and inheriting a 'long' allele leads to a threefold increase in risk of developing autism. This finding represents the first genetic factor consistently predisposing to autism in several distinct patient samples, and links autism to a plausible neurodevelopmental mechanism. Although 'long' reelin gene alleles characterize only 20% of their patients, this result fits exactly with expected single gene contributions to a complex disorder, such as autism.
Genomic organization of the SLC1A1/EAAC1 gene and mutation screening in early-onset obsessivecompulsive disorder J Veenstra-VanderWeele, S-J Kim, D Gonen, GL Hanna, BL Leventhal, EH Cook A small genome screen in pediatric obsessive-compulsive disorder found a non-parametric linkage peak in a region on chromosome 9 that contains SLC1A1, a gene that encodes for the neuronal glutamate transporter protein, EAAC1. The genomic organization of SLC1A1 was established. Following this, the coding region of the gene was sequenced in probands from each of the seven families in the genome screen, as well as in 10 control subjects. While no mutations were found that change the predicted sequence of the protein, a number of polymorphisms were found that allowed further study of the gene. The polymorphisms studied did not show significant linkage disequilibrium with pediatric OCD in their small sample, but they may prove useful for studies of SLC1A1 in other disorders.
An in-frame deletion in the ␣ 2C adrenergic receptor is common in African- Americans J Feng, J Zheng, J Gelernter, H Kranzler, E Cook, D Goldman, IR Jones, N Craddock, LL Heston, L Delisi, L Peltonen, WP Bennett, SS Sommer The authors report a new polymorphism of the ␣ 2C adrenergic receptor which has an allelic frequency of 40% in Afrian-Americans and 4% in Caucasians. This variant has potential clinical significance because clozapine binds to the prevalent form of the ␣ 2C adrenergic receptor with greater affinity than any other known receptor, but its binding to this new variant is unknown. Since clozapine is an atypical neuroleptic used for treatment-resistant schizophrenics, differences in receptor binding affinities could account for variations in clinical response. For example, this deletion polymorphism might account for some of the treatment-resistant cases of schizophrenia or confer a personality trait; a variant of similar type and location in the type 4 dopamine receptor, another member of the G-coupled protein receptor family, is associated with attention deficit hyperactivity disorder and novelty-seeking behavior. Disrupted In Schizophrenia 1 (DISC1) is a gene that is directly disrupted by a (q42.1; q14.3) translocation cosegregating with schizophrenia and related psychiatric illness. An antisense gene, DISC2, is also disrupted by the same translocation. Further study of both genes is required to assess their potential involvement in the aetiology of psychiatric disorders. In order to evaluate DISC1, its genomic structure has been determined and the locations of nearby polymorphic markers identified. This information will provide the basis for association studies and further analysis of the gene. Furthermore, marker identification has placed DISC1 within a critical region on chromosome 1 identified by a number of other studies.
Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizo-paranoid and residual subtypes of schizophrenia P Kaiser, P-B Tremblay, J Schmider, M Henneken, M Dettling, B Mü ller-Oerlinghausen, R Uebelhack, I Roots, J Brockmö ller
The serotonin transporter may play a role in the pathogenesis of neuropsychiatric disease and in the response to antipsychotic drugs. Therefore the authors analyzed the impact of the 44-bp deletion polymorphism and the 17-bp variable number of tandem repeat (VNTR) of this transporter in 684 schizophrenic patients and 587 healthy subjects. Schizo-affective patients were more frequently homozygous for the 44-bp insertion variant (Odds ratio, OR: 1.6, 95% confidence interval, CI: 1.1-2.3). Patients with schizo-paranoid schizophrenia were more frequently homozygous for the STin2.12 allele of the 17-bp VNTR than controls (OR: 1.4, CI: 1.1-1.8) or all other schizophrenic patients (OR: 1.6, CI: 1.2-2.3). The rare STin2.9 allele represented a risk factor for the residual type of schizophrenia (OR: 6.4, CI: 2.5-16.2). Both polymorphisms did not predict the therapeutic outcome as measured by the positive and negative symptoms scale.
Structure and polymorphisms of the human metabotropic glutamate receptor type 2 gene (GRM2): analysis of association with schizophrenia A Joo, H Shibata, H Ninomiya, H Kawasaki, N Tashiro, Y Fukumaki
Subtype 2 metabotropic glutamate receptor (mGluR2) gene (GRM2) is one of the possible candidate genes for schizophrenia. To evaluate involvement of mGluR2 in the pathogenesis of schizophrenia, the authors isolated the human mGluR2 gene and determined the transcrip-tion initiation site, the entire nucleotide sequence and the chromosomal localization. The hmGluR2 gene spans 13 kb with six exons, including one non-coding exon. The gene was mapped to chromosome 3p12-p11 using Radiation Hybrid Panel analysis. The authors screened polymorphisms by SSCP analysis in the coding exons of the gene and identified 13 polymorphisms including 10 missense, one silent mutation and two one-base substitutions in the 5Ј-untranslated region. They genotyped 213 Japanese schizophrenics and 220 controls to study the association of polymorphisms in the mGluR2 gene with schizophrenia. Since no statistically significant differences in allele frequencies of each polymorphism were observed, these polymorphisms apparently do not play a major role in schizophrenia.
Polymorphism in SNAP29 gene promoter region associated with schizophrenia T Saito, F Guan, DF Papolos, N Rajouria, CSJ Fann, HM Lachman
Genetic studies indicate that a subset of patients with schizophrenia and bipolar disorder (manic depressive illness) have a mutation in a gene on chromosome 22 that may predispose them to psychiatric problems. So far, the target gene has not been identified. The authors have systematically analyzed a potential candidate gene on chromosome 22, known as SNAP-29, for mutations that could be involved in the development of bipolar disorder or schizophrenia. They identified a mutation in the region of the SNAP-29 gene that is postulated to help determine the degree to which the gene is activated in brain cells. The frequency of this mutation in patients with schizophrenia, but not bipolar disorder, was found to significantly differ from the frequency found in normal control subjects. The findings suggest SNAP-29 is a potential candidate gene for chromosome 22-associated schizophrenia.
Evidence for association of the myo-inositol monophosphatase 2 (IMPA2) gene with schizophrenia in Japanese samples
In their search for candidate genes for functional psychoses on the chromosome 18p11,2, the authors cloned IMPA2, a novel human myo-inositol monophosphatase. In the present study, they identified seven single nucleotide polymorphisms (SNPs), including a novel missense mutation in Japanese samples. Combined with the three that they have reported previously, the authors have detected a total of 10 SNPs that map to three regional clusters in the IMPA2 gene. Because markers within each cluster were found to be in linkage disequilibrium, one marker from each cluster was chosen for association testing: 58GϾA, IVS1-15GϾA and 800CϾT from clusters 1, 2, and 3, respect-
Molecular Psychiatry
ively. All three SNPs showed significant genotypic association with schizophrenia, but not with affective disorder. These findings increase the relevance of 18p11.2 to schizophrenia susceptibility, suggesting that IMPA2 or a gene nearby may contribute to the overall genetic risk for schizophrenia in the Japanese.
Mutation analysis of the NMDAR2B (GRIN2B) gene in schizophrenia T Ohtsuki, K Sakurai, H Dou, M Toru, K YamakawaKobayashi, T Arinami
Pharmacological evidence from humans and animal models suggests that dysfunction of neurotransmission medicated by NMDA receptors may contribute to the signs and symptoms of schizophrenia. The regional expression pattern of the NMDAR2B gene suggests that it may be particularly relevant to frontal cortical neurotransmission. The authors searched for mutations in the NMDAR2B subunit gene (GRIN2B) in schizophrenic patients and detected eight synonymous single nucleotide polymorphisms. Two weak but statistically significant findings were excesses of homozygosity for the polymorphisms in the 3Ј region of the gene in schizophrenic patients and higher frequency of the G allele of the 366C/G polymorphism in patients than in controls. Since the association is not obvious, further analysis of this gene in independent samples is important to examine the possible association between the GRIN2B gene and schizophrenia.
An association of a 5-HT5a receptor polymorphism, pro15ser, to schizophrenia N Iwata, N Ozadi, T Inada, D Goldman
Schizophrenia is a common psychiatric disorder which is substantially heritable, meaning that some of the vulnerability to schizophrenia is due to inherited differences in genes involved in the development and function of the brain. These investigators studied a human polymorphism (common genetic variant) which alters the protein structure of a serotonin (neurotransmitter receptor) known as 5HT5A. This receptor had been implicated in the actions of LSD, a hallucinogen which produces a psychotic-like state in healthy people. They compared 249 unrelated Japanese schizophrenia patients and 253 unrelated controls from the same population. A Ͼ3-fold, highly significant difference (P Ͻ 0.0001) in the frequency of the amino acid substitution was seen between schizophrenia and controls. Although Japanese patients were compared to Japanese controls, case-control studies have a potential for falsepositive results due to problems with matching for population of origin. Also, pending replication, chance findings can occur.
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Family-based studies of monoaminergic gene polymorphisms among Indians with schizophrenia P Semwal, S Prasad, T Bhatia, SN Deshpande, J Wood, VL Nimgaonkar, BK Thelma Schizophrenia is a common disorder with a proven genetic etiology. In order to help pinpoint the causative genetic factors, the authors investigated variations in four 'candidate genes' implicated from previous studies. These included the genes encoding serotonin 2A receptor, tryptophan hydroxylase, catechol-O-methyl transferase and dopamine transporter. They employed a familybased association design (Transmission Disequilibrium Test). Their sample included 179 Indian families with one or more individuals having schizophrenia. No significant association was detected. The non-significant results imply that the genes are not involved in the etiology of schizophrenia. Alternatively, their sample may have insufficient power to detect such effects. Tardive dyskinesia (TD) is a long-term adverse effect of classical antipsychotic drugs that block dopamine D2 receptors. Serotonin receptor blockade has been proposed as a common mechanism contributing to the low adverse effects profile of atypical antipsychotic drugs. The authors have examined the association of three genetic polymorphic sites in the serotonin 2A receptor gene (HTR2A) with susceptibility for TD. Schizophrenia patients with and without TD, matched for antipsychotic drug exposure and other relevant variables, and 96 normal control subjects, were studied. Two of the polymorphic sites, the promoter A-1438G and the silent T102C were in complete linkage disequilibrium. There was a significant excess of 102C and -1438G alleles and genotypes in the patients with TD compared to the patients without TD and matched normal control subjects. The 102CC and the -1438GG genotypes were associated with significantly higher body trunk dyskinesia scores and more incapacitation. In contradiction, the his452tyr polymorphism showed no association with TD. These findings suggest that the 5-HT2A receptor gene is significantly associated with susceptibility to TD in patients with chronic schizophrenia. Previously reported association of the T102C and A-1438G polymorphisms in the 5-HT2A receptor gene with schizophrenia may reflect association of a sub-group of patients with a susceptibility to abnormal involuntary movements related to antipsychotic drug exposure. antipsychotic drugs. Family studies and animal models lend evidence for hereditary predisposition to TD. The authors searched for the molecular genetic basis of TD using a genetic association strategy in patients with schizophrenia. They characterized their patient sample for the severity of TD using the Abnormal Involuntary Movement Scale (AIMS). Subsequently, the authors did not find any significant relationship between TD and molecular genetic differences in HTR2A among patients, despite controlling for potential confounding variables (age, gender, and ethnicity) . Theoretically, central serotonergic function can be subject to genetic regulation at various other levels including the rate of serotonin synthesis, release, reuptake, and degradation. Further studies evaluating in tandem multiple candidate genes relevant for the serotonergic system are warranted to identify the molecular genetic basis of antipsychotic-induced movement disorders.
Function polymorphism within the promoter of the serotonin transporter gene is associated with severe hyperkinetic disorders G Seeger, P Schloss, MH Schmidt
In children, hyperkinetic disorder (HD) with conduct disorder (CD) and without CD and attentiondeficit/hyperactivity disorder (ADHD) is known to be comorbid with psychiatric disorders some of which are related to disturbed serotonergic neurotransmission. The efficiency of serotonergic signaling is related to the concentration of synaptic serotonin and is controlled by the serotonin transporter (5-HTT), which removes serotonin out of the synaptic cleft. The activity of the transporter protein depends on a 5-HTT-linked polymorphism in its promotor region with a L/L genotype being more active than L/S or S/S genotypes. Genotyping for 5-HTT revealed in contrast to controls an enhanced expression of the L/L genotype in HD patients with CD and a significant overexpression of L/L in HD patients without CD. This finding provides evidence for an association between the 5-HTT polymorphism and hyperkinetic disorder implying that serotonergic neurotransmission might be affected in this disease.
Variability in the 5-HT2A receptor gene is associated with seasonal pattern in major depression B Arias, B Gutié rrez, L Pintor, C Gastó , L Fañ aná s
The 5-HT2A receptor gene is a candidate gene for depression due to its role in the serotonin neurotransmission pathway and the action mechanism of certain antidepressant drugs. Some authors have described the relationship between genetic variability in serotonin receptor genes and different profiles of seasonality in patients with affective disorders, suggesting the possible role of certain allelic variants of these genes in the seasonal modulation of depressive symptom outcome. A sample of 159 patients diagnosed with major depression and 164 matched controls were used to test the possible association between the 5-HT2A receptor gene and major depression. The authors found an association between the allele C102 and seasonal pattern in a subset of patients with major depression. This could suggest that major depression is a clinical and etiologically heterogeneous disease.
Association of anorexia nervosa with the high activity allele of the COMT gene: a family-based study in Israeli patients A Frisch, N Laufer, Y Danziger, E Michaelovsky, S Leor, C Carel, D Stein, S Fenig, M Mimouni, A Apter, A Weizman Anorexia nervosa (AN) is a common, severe and disabling psychiatric disorder, characterized by profound weight loss and body image disturbance. Family and twin studies indicate a significant genetic contribution and pharmacological data suggest possible dysunfction of the serotonergic and dopaminergic pathways. Cathechol-O-methyltransferase (COMT) is a candidate gene for mediating susceptibility to AN since it is involved in the dopamine catabolism and because its functional polymorphism (Val/Met 158) determines high (H) and low (L) enzymatic activity alleles. Fiftyone Israeli AN patients and their parents were genotyped with the COMT polymorphism. Using the haplotype relative risk (HRR) method it was found that the frequency of the H allele among alleles transmitted to AN patients from their parents was significantly higher Molecular Psychiatry than in those not transmitted. Transmission disequilibrium test (TDT) revealed that out of 49 heterozygote parents the H allele was transmitted to AN patients 33 times while the L allele was transmitted only 16. The authors' study suggests that the COMT gene is associated with genetic susceptibility to AN, and that individuals homozygous for the high activity allele (HH) have a two-fold increased risk for development of the disorder.
Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro HF Kim, EJ Weeber, JD Sweatt, AL Stoll, LB Marangell Recent clinical data indicate that omega-3 fatty acids are effective mood stabilizers for patients with bipolar disorder. Known mood stabilizers, lithium and valproate, appear to affect protein kinase C (PKC) activity. The current study was undertaken to characterize the effects and potency of the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) on PKC activity in vitro, using the catalytic domain of protein kinase C beta from rat brain. Both DHA and EPA inhibited PKC activity at concentrations as low as 10 mol l −1
. Thus, omega-3 fatty acids may suppress aberrant signal transduction, which may be involved in the pathogenesis of bipolar disorder. J Licinio, MD Editor
